Клинические рекомендации / Кардиоваскулярная+профилактика

representatives of 10 societies and by invited experts)Developed with the

special contribution of the European Association for Cardiovascular

Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315-81.

689.

17.3.4

Муромцева ГА, Концевая АВ, Константинов ВВ, Артамонова ГВ,

Гатагонова ТМ, Дупляков ДВ, Ефанов АЮ, Жернакова ЮВ, Ильин ВА,

Конради АО, Либис РА, Минаков АВ, Недогода СВ, Ощепкова ЕВ,

Романчук СА, Ротарь ОП, Трубачева ИА, Деев АД, Шальнова СА, Чазова

ИЕ, Шляхто ЕВ, Бойцов СА. Распространенность факторов риска

неинфекционных заболеваний в российской популяции в 2012-2013

гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и

профилактика 2014; 13(6): 4–11.

690.

17.3.5

Pogosova N, Saner H, Pedersen SS, Cupples ME, McGee H, Hofer S, Doyle

F, Schmid JP, von Kanel R. Psychosocial aspects in cardiac rehabilitation:

from theory to practice. A position paper from the Cardiac Rehabilitation

Section of the European Association of Cardiovascular Prevention and

Rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol

2015; 22: 1290–1306.

691.

17.3.6

Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG,

Steinkellner A. Influence of patient sex and gender on medication use,

adherence, and prescribing alignment with guidelines. J Womens Health

(Larchmt) 2014; 23(2): 112-119. doi: 10.1089/jwh.2012.3972. Epub 2013

Nov.

692.

17.3.7

Shrank WH, Liberman JN, Fischer MA, Kilabuk E, Girdish C, Cutrona S,

Brennan T, Choudhry NK. Are caregivers adherent to their own

medications? JAmPharmAssoc (2003) 2011; 51(4):492-498.

693.

17.3.8

Погосова НВ, Оганов РГ, Бойцов СА, Аушева АК, Соколова ОЮ,

Курсаков АА, Поздняков ЮМ, Салбиева АО, Юсубова АИ, Лельчук ИН,

Гусарова ТА, Гомыранова НВ, Сказин НА, Елисеева НА, Ахмедова ЭБ,

Бедейникова КК, Ковригина МН. Медикаментозная терапия у

пациентов с ишемической болезнью сердца в России и Европе:

результаты российской части международного многоцентрового

исследования EUROASPIRE IV. Кардиология 2016; 12: 5-11.

694.

17.3.9

Погосова НВ, Соколова ОЮ, Юферева ЮМ, Осипова ИВ, Рямзина ИН от

имени группы исследователей российской части исследования

EuroCaRe-D. Первые результаты анализа российской части

европейского регистра по кардиореабилитации (European Cardiac

Rehabilitation Database – EuroCaReD) с участием 13 стран. Кардиология

2015; 55 (2): 49-56.

695.

17.3.10

Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ.

Hypertensive pregnancy disorders and subsequent cardiovascular

morbidity and type 2 diabetes mellitus in the mother. Hypertension 2009;

53: 944–51.

696.

17.3.11

Skjaerven R, Wilcox AJ, Klungsoyr K, Irgens LM, Vikse BE, Vatten LJ, Lie RT.

Cardiovascular mortality after pre-eclampsia in one child mothers:

prospective, population based cohort study. BMJ 2012; 345: e7677.

326: 845.

698.

17.3.13

Engeland A, Bjorge T, Daltveit AK, Skurtveit S, Vangen S, Vollset SE, Furu K.

Risk of diabetes after gestational diabetes and preeclampsia. A registry-

based study of 230,000 women in Norway. Eur J Epidemiol 2011; 26:157-

163.

699.

17.3.14

Lykke JA, Paidas MJ, Damm P, Triche EW, Kuczynski E, Langhoff-Roos J.

Preterm delivery and risk of subsequent cardiovascular morbidity and

type-II diabetes in the mother. BJOG 2010; 117: 274-281.

700.

17.3.15

Marin R, Gorostidi M, Portal CG, Sanchez M, Sanchez E, Alvarez J. Long-

term prognosis of hypertension in pregnancy. Hypertens Pregnancy

2000;19:199–209.

701.

17.3.16

Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus

after gestational diabetes: a systematic review and meta-analysis. Lancet

2009; 373: 1773-1779.

702.

17.3.17

Venkataraman H, Sattar N, Saravanan P. Postnatal testing following

gestational diabetes: time to replace the oral glucose tolerance test?

Lancet Diabetes Endocrinol 2015; 3: 754-756.

703.

17.3.18

Hastie CE, Smith GC, Mackay DF, Pell JP. Maternal risk of ischaemic heart

disease following elective and spontaneous pre-term delivery:

retrospective cohort study of 750 350 singleton pregnancies. Int J

Epidemiol 2011; 40(4): 914-919.

704.

17.3.19

Heida KY, Velthuis BK, Oudijk MA, Reitsma JB, Bots ML, Franx A, vanDunné

FM; Dutch Guideline Development Group on Cardiovascular Risk

Management after Reproductive Disorders. Cardiovascular disease risk in

women with a history of spontaneous preterm delivery: A systematic

review and meta-analysis. Eur J Prev Cardiol 2016; 23(3): 253-263.

705.

17.3.20

Parker DR, Lu B, Sands-Lincoln M, Kroenke CH, Lee CC, O'Sullivan M, Park

HL, Parikh N, Schenken RS, Eaton CB. Risk of cardiovascular disease among

postmenopausal women with prior pregnancy loss: the women's health

initiative. Ann Fam Med 2014 ; 12(4): 302-309.

706.

17.3.21

Bonamy AK, Parikh NI, Cnattingius S, Ludvigsson JF, Ingelsson E. Birth

characteristics and subsequent risks of maternal cardiovascular disease:

effects of gestational age and fetal growth. Circulation 2011; 124: 2839–

2846.

707.

17.3.22

Sanghavi M, Kulinski J, Ayers CR, et al. Association between number of live

births and markers of subclinical atherosclerosis: The Dallas Heart Study.

European journal of preventive cardiology 2016; 23(4): 391-399.

doi:10.1177/2047487315571891.

708.

17.3.23

Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD,

Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE,

Bittner V, Hodgson TK, RogersW, Pepine CJ. Postmenopausal women with

a history of irregular menses and elevated androgen measurements at

high risk for worsening cardiovascular event-free survival: results from the

National Institutes of Health–National Heart, Lung, and Blood Institute

sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol

Metab 2008; 93: 1276-1284.

matched, reference controls: a retrospective, observational study. J Clin

Endocrinol Metab 2012; 97: 3251-3260.

710.

17.3.25

Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance,

type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a

systematic review and meta-analysis. Hum Reprod Update 2010; 16: 347–

363.

711.

17.3.26

Hong JS, Yi SW, Kang HC, Jee SH, Kang HG, Bayasgalan G, Ohrr H. Age at

menopause and cause-specific mortality in South Korean women:

Kangwha Cohort Study. Maturitas 2007; 56: 411–419.

712.

17.3.27

Canoy D, Beral V, Balkwill A, Wright FL, Kroll ME, Reeves GK, Green J,

Cairns BJ; Million Women Study Collaborators. Age at menarche and risks

of coronary heart and other vascular diseases in a large UK cohort.

Circulation 2015; 131(3): 237-44.

713.

17.3.28

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick

ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM,

Ockene J; Writing Group for the Women's Health Initiative Investigators.

Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal

Women Principal Results From the Women's Health Initiative Randomized

Controlled Trial. JAMA 2002; 288(3): 321–333.

714.

17.3.29

Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for

coronary heart disease prevention with hormone therapy: past, present

and future in perspective. Climacteric 2012; 15(3): 217-28.

715.

17.3.30

Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice

RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende

J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford

SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller

LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon

MS, Van Horn L, Vitolins MZ, Wallace RB. Menopausal hormone therapy

and health outcomes during the intervention and extended poststopping

phases of the Women's Health Initiative randomized trials. JAMA 2013;

310(13): 1353-68.

716.

17.3.31

Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing

cardiovascular disease in post-menopausal women. Cochrane Database

Syst Rev 2015; (3): CD002229.

717.

17.3.32

Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS

Recommendations on women's midlife health and menopause hormone

therapy. Climacteric 2016 ; 19(2): 109-50.

18. Антитромбоцитарная

718.

18.1

Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of

clopidogrel in addition to aspirin in patients with acute coronary

syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–

502.

719.

18.2

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb

S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J,

Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in

patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-

2015.

720.

18.3

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C,

273

Horrow J, Husted S, James S, Katus H, MahaffeyKW, Scirica BM, Skene A,

Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus

clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;

361: 1045-1057.

721.

18.4

Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park

BE, Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y. A new strategy

for discontinuation of dual antiplatelet therapy: the RESET Trial (REal

Safety and Efficacy of 3-month dual antiplatelet Therapy following

Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;

60: 1340-1348.

722.

18.5

Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB

3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ

Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmao

M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL. Three vs twelve

months of dual antiplatelet therapy after zotarolimus-eluting stents: the

OPTIMIZE randomized trial. JAMA 2013; 310: 2510-2522.

723.

18.6

Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH,

Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY,

Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK,

Jang Y, Kim HS. Six-month versus 12-month dual antiplatelet therapy after

implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus

Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized,

multicenter study. Circulation 2012; 125: 505-513.

724.

18.7

Schulz-Schupke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y,

Adriaenssens T, Tolg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C,

Mudra H, von Hodenberg E, Wohrle J, Angiolillo DJ, von Merzljak B, Rifatov

N, Kufner S, Morath T, Feuchtenberger A, Ibrahim T, Janssen PW, Valina C,

Li Y, Desmet W, Abdel-Wahab M, Tiroch K, Hengstenberg C, Bernlochner I,

Fischer M, Schunkert H, Laugwitz KL, Schomig A, Mehilli J, Kastrati A. ISAR-

SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12

months of clopidogrel therapy after drug-eluting stenting. Eur Heart J

2015; 36: 1252-1263.

725.

18.8

Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG,

Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff

MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP,

Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM. Twelve or 30 months of dual

antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371:

2155-2166.

726.

18.9

Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G,

Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P,

Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott

SD, Held P, Braunwald E, Sabatine MS. Long-term use of ticagrelor in

patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-

1800.

727.

18.10

Antithrombotic Trialists’ Collaboration, Baigent C, Blackwell L, Collins R,

Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T,

Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and

secondary prevention of vascular disease: collaborative meta-analysis of

individual participant data from randomised trials. Lancet 2009; 373:

274

1849-1860.

728.

18.11

De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke and

other vascular events in patients with vascular disease. Cochrane

Database Syst Rev 2007; 3: CD001820.

729.

18.12

Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y,

Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L,

Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson

K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V,

Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW. Aspirin and

extended-release dipyridamole versus clopidogrel for recurrent stroke. N

Engl J Med 2008; 359: 1238-251.

730.

18.13

Farrell B, Godwin J, Richards S,Warlow C. The United Kingdom transient

ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg

Psychiatry 1991; 54: 1044-1054.

731.

18.14

Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP,

Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P. A

comparison of warfarin and aspirin for the prevention of recurrent

ischemic stroke. N Engl J Med 2001; 345: 1444-451.

732.

18.15

Liu M, Counsell C, Sandercock P. Anticoagulants for preventing recurrence

following ischaemic stroke or transient ischaemic attack. Cochrane

Database Syst Rev 2000; 2: CD000248.

733.

18.16

Fuster V, Bhatt DL, Califf RM, Michelson AD, Sabatine MS, Angiolillo DJ,

Bates ER, Cohen DJ, Coller BS, Furie B, Hulot JS, Mann KG, Mega JL,

Musunuru K, O'Donnell CJ, Price MJ, Schneider DJ, Simon DI, Weitz JI,

Williams MS, Hoots WK, Rosenberg YD, Hasan AA. Guided antithrombotic

therapy: current status and future research direction: report on a National

Heart, Lung and Blood Institute working group. Circulation 2012; 126(13):

1645-62.

734.

18.17

Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on

cardiovascular disease prevention in clinical practice: The Sixth Joint Task

Force of the European Society of Cardiology and Other Societies on

Cardiovascular Disease Prevention in Clinical Practice (constituted by

representatives of 10 societies and by invited experts)Developed with the

special contribution of the European Association for Cardiovascular

Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315-81.

735.

18.18

Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S,

Sugawara M, Ando K, Murata M, Yokoyama K, Ishizuka N. Low-dose aspirin

for primary prevention of cardiovascular events in Japanese patients 60

years or older with atherosclerotic risk factors: a randomized clinical trial.

JAMA 2014; 312: 2510–2520.

736.

18.19

Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P,

Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW,

Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg

PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J,

Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of

atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.

737.

18.20

De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G,

Valentini U, Nicolucci A. Aspirin and Simvastatin Combination for

275

Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a

randomized study of the efficacy of low-dose aspirin in the prevention of

cardiovascular events in subjects with diabetes mellitus treated with

statins. Trials 2007; 8: 21.

738.

18.21

Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE) Trial.

http://www.arrivestudy.com.

739.

18.22

Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of

randomised trials of antiplatelet therapy for prevention of death,

myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–

86.

740.

18.23

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel

versus aspirin inpatients at risk of ischaemic events (CAPRIE). Lancet 1996;

348: 1329–1339.

741.

18.24

Udell JA, Bonaca MP, Collet J-P, Lincoff AM, Kereiakes DJ, Costa F, Lee

CW, Mauri L, Valgimigli M, Park SJ, Montalescot G, Sabatine M,

Braunwald E, Bhatt DL. Long-term dual antiplatelet therapy for secondary

prevention of cardiovascular events in the subgroup of patients with

previous myocardial infarction: a collaborative meta-analysis of

randomized trials. Eur Heart J 2016; 37: 390-399.

742.

18.25

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P,

Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN,

Schneider D, Sun X, Verheugt FW, Gibson CM. Rivaroxaban in patients

with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.

743.

18.26

Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax J,

Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K,

Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker

S. 2015 ESC Guidelines for the management of acute coronary syndromes

in patients presenting without persistent ST-segment elevation: Task Force

for the management of acute coronary syndromes in patients presenting

without persistent ST-segment elevation of the European Society of

Cardiology (ESC). Eur Heart J 2016; 37: 267—315

744.

18.27

Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G,

Hamm C, Head S J, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser

U, Laufer G, Neumann FJ, Richter D J, Schauerte P, Uva MS, Stefanini GG,

Taggart DP, Torracca L, Valgimigli M, Wijns Wi, Witkowski A. 2014

ESC/EACTS Guidelines on myocardial revascularization. The Task Force on

Myocardial Revascularization of the European Society of Cardiology (ESC)

and the European Association for Cardio-Thoracic Surgery (EACTS)

Developed with the special contribution of theEuropeanAssociation of

Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35:

2541-2619.

745.

18.28

Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R.

Double blind trial of aspirin in primary prevention of myocardial infarction

in patients with stable chronic angina pectoris. The Swedish Angina

Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340: 1421-1425

746.

18.29

Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A,

Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt A K,

Hulot J-S, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M,

276

Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T,

Kownator S, Mazzolai L, Naylor AR, Roffi M, Röther J, Sprynger M, Tendera

M, Tepe G, Venermo M, Vlachopoulos C, Desormais I. 2017 ESC Guidelines

on the Diagnosis and Treatment of Peripheral Arterial Diseases, in

collaboration with the European Society for Vascular Surgery (ESVS):

Document covering atherosclerotic disease of extracranial carotid and

vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed

by: the European Stroke Organization (ESO)The Task Force for the

Diagnosis and Treatment of Peripheral Arterial Diseases of the European

Society of Cardiology (ESC) and of the European Society for Vascular

Surgery (ESVS).Eur Heart J 2017. doi: 10.1093/eurheartj/ehx095.

754.

18.37

Anand S et al. COMPASS PAD: Cardiovascular Outcomes for People Using

Anticoagulation Strategies trial: Results in patients with peripheral artery

disease. European Society of Cardiology 2017 Congress. August 27, 2017;

Barcelona, Spain.

755.

18.38

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M,

Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J,

Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron

Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R,

Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B,

Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J,

Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P,

Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL,

Zeppenfeld K. 2016 ESC Guidelines for the management of atrial

fibrillation developed in collaboration with EACTS. Eur Heart J 2016;

37(38): 2893-2962.

756.

18.39

Vadmann H, Nielsen PB, Hjortshoj SP, Riahi S, Rasmussen LH, Lip GY,

Larsen TB. Atrial flutter and thromboembolic risk: a systematic review.

Heart 2015; 101: 1446-1455.

757.

18.40

Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M,

Avezum A, Diaz R, Hohnloser SH, Lewis BS, Shestakovska O,Wang J,

Connolly SJ. Risk of ischaemic stroke according to pattern of atrial

fibrillation: analysis of 6563 aspirintreated patients in ACTIVE-A and

AVERROES. Eur Heart J 2015; 36: 281-287.

758.

18.41

Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY,

Fauchier L. Pattern of atrial fibrillation and risk of outcomes: the Loire

Valley Atrial Fibrillation Project. Int J Cardiol 2013; 167: 2682-2687.

759.

18.42

Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-C, Hacke W,

Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. Updated European Heart

Rhythm Association Practical Guide on the use of non-vitamin K antagonist

anticoagulants in patients with non-valvular atrial fibrillation. Europace

2015; 17: 1467-1507

760.

18.43

Кардиоваскулярная профилактика. Национальные рекомендации.

Разработаны Комитетом экспертов Всероссийского научного

общества кардиологов и Национальным на¬учным обществом

«Кардиоваскулярная терапия и профилактика». Кардиоваскулярная

терапия и профилактика 2011; 10(6).

use in 426 patients with atrial fibrillation undergoing percutaneous

coronary intervention and stent implantation implications for bleeding risk

and prognosis. J Am Coll Cardiol 2008; 51: 818–825.

762.

18.45

Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B,

Lancellotti P, Lansac E, Muñoz DR, Rosenhek R, Sjögren J, Tornos Mas P,

Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL. 2017

ESC/EACTS Guidelines for the management of valvular heart disease: The

Task Force for the Management of Valvular Heart Disease of the European

Society of Cardiology (ESC) and the European Association for Cardio-

Thoracic Surgery (EACTS). Eur Heart J 2017.

doi: 10.1093/eurheartj/ehx391.

763.

18.46

Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding

complications in patients with mechanical heart valve prostheses.

Circulation 1994; 89: 635–641

764.

18.47

Mok CK, Boey J, Wang R, Chan TK, Cheung KL, Lee PK, Chow J, Ng RP, Tse

TF. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the

prevention of prosthetic heart valve thromboembolism: a prospective

randomized clinical trial. Circulation 1985; 72: 1059–1063

765.

18.48

Heneghan C, Ward A, Perera R, Bankhead C, Fuller A, Stevens R, Bradford

K, Tyndel S, Alonso-Coello P, Ansell J, Beyth R, Bernardo A, Christensen TD,

Cromheecke ME, Edson RG, Fitzmaurice D, Gadisseur AP, Garcia-Alamino

JM, Gardiner C, Hasenkam JM, Jacobson A, Kaatz S, Kamali F, Khan TI,

Knight E, Kortke H, Levi M, Matchar D, Menendez-Jandula B, Rakovac I,

Schaefer C, Siebenhofer A, Souto JC, Sunderji R, Gin K, Shalansky K, Voller

H, Wagner O, Zittermann A. Self-monitoring of oral anticoagulation:

systematic review and meta-analysis of individual patient data. Lancet

2012; 379: 322–334

766.

18.49

Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D,

Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T,

Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sarafoff N. Duration of

triple therapy in patients requiring oral anticoagulation after drug-eluting

stent implantation: the ISAR-TRIPLE Trial. J Am Coll Cardiol 2015; 65:

1619–1629.

767.

18.50

Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P,

Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip

GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in

patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375:

2423–2434

768.

18.51

Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP,

Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van‘t Hof

AW, ten Berg, JM, WOEST study investigators. Use of clopidogrel with or

without aspirin in patients taking oral anticoagulant therapy and

undergoing percutaneous coronary intervention: an open-label,

randomised, controlled trial. Lancet 2013; 381: 1107–1115

769.

18.52

Lamberts M, Gislason GH, Lip GY, Lassen JF, Olesen JB, Mikkelsen AP,

Sorensen R, Kober L, Torp-Pedersen C, Hansen ML. Antiplatelet therapy

for stable coronary artery disease in atrial fibrillation patients taking an

oral anticoagulant: a nationwide cohort study. Circulation 2014; 129:

1577–1585

279

770.

18.53

Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP,

Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y,

Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F, RE-ALIGN

Investigators. Dabigatran versus warfarin in patients with mechanical

heart valves. N Engl J Med 2013; 369: 1206–1214

771.

18.54

Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian

AA, Klein RC, Le H, Schulman S, Murad MH. Prevention of VTE in

Nonsurgical Patients Antithrombotic Therapy and Prevention of

Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based

Clinical Practice Guidelines. Chest 2012; 141: 195–226

772.

18.55

Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N,

Gibbs J SR, Huisman M, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J,

Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH,

Schindler TH, Svitil P, Noordegraaf AV, Zamorano JL, Zompatori M. 2014

ESC Guidelines on the diagnosis and management of acute pulmonary

embolism. The Task Force for the Diagnosis and Management of Acute

Pulmonary Embolism of the European Society of Cardiology (ESC)

Endorsed by the European Respiratory Society (ERS). Eur Heart J 2014; 35:

3033-3069

773.

18.56

Kearon C., Akl E.A., Ornelas J., Blaivas A., Jimenez D., Henri Bounameaux,

Menno Huisman, Christopher S. King, Timothy A. Morris, Namita Sood,

Scott M. Stevens, Janine R. E. Vintch, Philip Wells, Scott C. Woller, Lisa

Moores. Antithrombotic Therapy for VTE Disease CHEST Guideline and

Expert Panel Report. Chest 2016; 149: 315-352

774.

18.57

Бокерия ЛА, Затевахин ИИ, Кириенко АИ, Андрияшкин АВ,

Андрияшкин ВВ, Арутюнов ГП, Баринов ВЕ, Бицадзе ВО, Бодыхов МК,

Бритов АН, Бутенко АВ, Вавилова ТВ, Воробьёва НА, Восканян ЮЭ,

Гавриленко АВ, Галстян ГМ, Гельфанд БР, Гиляров МЮ, Голубев ГШ,

Замятин МН, Золотухин ИА, Кобалава ЖД, Кательницкий ИИ,

Копёнкин СС, Кузнецов МР, Леонтьев СГ, Лобастов КВ, Лубнин АЮ,

Макацария АД, Моисеев ВС, Момот АП, Острякова ЕВ, Панченко ЕП,

Переходов СН, Пирадов МА, Поддубная ИВ, Покровский АВ, Проценко

ДН, Прудков МИ, Прядко СИ, Пырегов АВ, Решетняк ТМ, Рябинкина

ЮВ, Сапелкин СВ, Семёнова МН, Смирнов СВ, Соколов ВА, Стаховская

ЛВ, Стойко ЮМ, Сулимов ВА, Сухих ГТ, Терещенко СН, Фокин АА,

Хруслов МВ, Шевела АИ, Шиманко АИ, Шулутко АМ, Явелов ИС,

Яхонтов ДИ. Российские клинические рекомендации по диагностике,

лечению и профилактике венозных тромбоэмболических осложнений

(ВТЭО). Флебология 2015; 9 (4): 3-52

19. Приверженность

775.

19.1

Sabate E. Adherence to long-term therapies: evidence for action. WHO

Geneva 2003.

776.

19.2

Osterberg L, Blaschke T. Adherence to medication. N Engl JMed 2005;

353(5): 487-497.

777.

19.3

McGinnis B, Olson KL, Magid D et al. Factors related to adherence to statin

therapy. Ann Pharmacother 2007; 41(11): 1805-11.